First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US

被引：0
|
作者：
Vieira, M. Cecilia [1 ]
Duncan, K. [1 ]
Hsu, W. -C. [2 ]
Ross, R. [2 ]
Benjumea, D. [2 ]
Vlahiotis, A. [1 ]
Li, B. [1 ]
Wilner, K. D. [3 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.61
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [21] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
    Kang, Liping
    Mai, Jianliang
    Liang, Weiting
    Zou, Qihua
    Huang, Caiwen
    Lin, Yongbin
    Liang, Ying
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] First-line management of metastatic non-small cell lung cancer: An Indian perspective
    Ghadyalpatil, Nikhil Suresh
    Pandey, Avinash
    Krishnamani, Iyer
    Srinivas, Chilukuri
    Rafiq, Shabnam J.
    Hingmire, Sachin S.
    Maturu, Nagarjuna
    Reddy, Ragotham
    Kumar, Kiran K.
    Sreekanth, K.
    Gurram, Bharath Chandra
    Parikh, P. M.
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (02) : 73 - +
  • [23] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
    Peravali, Monica
    Ahn, Jaeil
    Chen, Kevin
    Rao, Suman
    Veytsman, Irina
    Liu, Stephen V.
    Kim, Chul
    ONCOLOGIST, 2021, 26 (08): : 694 - 700
  • [24] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [25] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
    Silva, S.
    Colquitt, J.
    Hatton, M. Q.
    Mohanamurali, J.
    Lee, C.
    Danson, S.
    Fisher, P.
    Woll, P.
    LUNG CANCER, 2014, 83 : S13 - S13
  • [26] Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
    Wang, Lin
    Liu, Ting
    Lin, Xihan
    Zhang, Yu
    Shi, Luwen
    You, Ruxu
    Liu, Jinyu
    IMMUNOTHERAPY, 2024, 16 (20-22) : 1217 - 1226
  • [27] First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
    Di Federico, A.
    Chen, M. F.
    Pagliaro, A.
    Ogliari, F. R.
    Stockhammer, P.
    Aldea, M.
    Grant, M.
    De Giglio, A.
    Alessi, J. V.
    Pecci, F.
    Gelsomino, F.
    Negrao, M. V.
    Ferrara, R.
    Awad, M.
    Riely, G. J.
    Ardizzoni, A.
    Planchard, D.
    Offin, M. D.
    Johnson, B. E.
    Ricciuti, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S826 - S827
  • [28] IMPACT OF ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (A/MNSCLC) ON PATIENTS IN THE US AND UK: SURVEY RESULTS
    Tapan, U.
    Wang, Y.
    Meng, Y.
    Yang, H.
    Shah, M.
    Bell, K.
    Liao, A.
    Ye, M.
    Solem, C.
    VALUE IN HEALTH, 2024, 27 (06) : S335 - S335
  • [29] Treatment patterns and overall survival in patients with BRAF-mutated metastatic non-small cell lung cancer
    Goyal, R. K.
    Kron, A.
    Wolf, J.
    Mazieres, J.
    Chouaid, C.
    Davis, K. L.
    Perrinjaquet, M.
    Knoll, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] BRAF mutations in non-small cell lung cancer
    Luk, Peter P.
    Yu, Bing
    Ng, Chiu Chin
    Mercorella, Belinda
    Selinger, Christina
    Lum, Trina
    Kao, Steven
    O'Toole, Sandra A.
    Cooper, Wendy A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (02) : 142 - 148
12345